XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe and is currently focused on regulatory approval and commercialization of medical products for European markets.
The bioscience company and its exclusive diagnostic partner, 3a-Diagnostics GmbH, are developing a point-of-care lateral flow test to detect COVID-19 viral RNA in patient saliva
Director Interviews
XPhyto Therapeutics achieves first purchases for their 25 minute PCR test
Director Interviews
XPhyto Therapeutics looking to hit milestones in 2021 as they move to development and manufacturing
